Peripheral plasma determinations of prostaglandin E in asthmatics

Area of Science:

• Biochemistry
• Pulmonology
• Pharmacology

Background:

• Prostaglandins, particularly prostaglandin E (PGE), are implicated in the pathophysiology of reversible airway diseases like asthma.
• Understanding the role of PGE in asthma and its interaction with bronchodilators is crucial for treatment optimization.

Purpose of the Study:

• To determine baseline plasma PGE levels in stable asthmatic patients and compare them to nonatopic controls.
• To investigate the effect of beta-adrenergic stimulation (terbutaline sulfate) on plasma PGE levels in asthmatics and controls.

Main Methods:

• Baseline plasma PGE levels were measured in 14 stable asthmatics and 28 nonatopic controls.
• Eight asthmatics and four controls received aerosolized terbutaline sulfate.
• Plasma PGE levels, pulmonary function, blood pressure, and heart rate were re-evaluated at 15, 30, and 60 minutes post-administration.

Main Results:

• Asthmatic patients exhibited significantly higher baseline plasma PGE levels (432 +/- 81) compared to nonatopic controls (89 +/- 9) (p < 0.002).
• Terbutaline administration did not cause a significant change in plasma PGE levels in either asthmatic or control groups over the 60-minute observation period.

Conclusions:

• There is a significant difference in baseline PGE levels between asthmatics and nonatopic individuals.
• Beta-adrenergic receptor stimulation appears to act independently of prostaglandins in modifying airway smooth muscle tone, consistent with current hypotheses involving adenyl cyclase activation.